22
Jun 2026
Pheno Therapeutics granted FDA IND clearance for lead multiple sclerosis therapeutic candidate PTD802
Pheno Therapeutics Limited. (Pheno), a clinical stage biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, today announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PTD802, the Company's lead therapeutic candidate.